



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Nemvaleukin alfa

Cat. No.:	HY-P99752
CAS No.:	2315268-27-8
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer ^{[1][2][3]} .																																																						
In Vitro	<p>Nemvaleukin alfa activates lymphocyte subsets from cynomolgus monkey and human samples, with EC₅₀s of 0.45-2.2 nM^[2]. Nemvaleukin alfa (0-100 nM, 30 min) induces the activation of intermediate-affinity IL-2R on human cells (HH cells)^[3]. Nemvaleukin alfa (0-100 nM, 30 min) induces pSTAT5 in NK cells with an EC₅₀ of 0.45 nM^[3]. Nemvaleukin alfa (0.5 nM, 5 days) induces the activation of effector lymphocytes isolated from human peripheral blood^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>																																																						
In Vivo	<p>Nemvaleukin alfa (6 mg/kg, s.c., every 4 days) inhibits SCLC tumor growth in mice^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td colspan="4">SCLC orthotopic model^[1]</td> </tr> <tr> <td>Dosage:</td> <td colspan="4">6 mg/kg</td> </tr> <tr> <td>Administration:</td> <td colspan="4">s.c., every 4 days</td> </tr> <tr> <td>Result:</td> <td colspan="4">Delayed tumor growth and prolonged survival.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td colspan="4">Male cynomolgus monkeys (PK Assay)^[2]</td> </tr> <tr> <td>Dosage:</td> <td colspan="4">0.3 or 1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td colspan="4">i.v. or s.c.</td> </tr> <tr> <td>Result:</td> <td colspan="4">Pharmacokinetic profile of Nemvaleukin alfa.</td> </tr> </table> <table border="1"> <thead> <tr> <th>Dose Route</th> <th>dose (mg/kg)</th> <th>C_{max} (ng/mL)</th> <th>T_{max} (h)</th> <th>T_{1/2} (h)</th> </tr> </thead> <tbody> <tr> <td>i.v.</td> <td>0.3</td> <td>6119</td> <td>0.083</td> <td>49.5</td> </tr> </tbody> </table>					Animal Model:	SCLC orthotopic model ^[1]				Dosage:	6 mg/kg				Administration:	s.c., every 4 days				Result:	Delayed tumor growth and prolonged survival.				Animal Model:	Male cynomolgus monkeys (PK Assay) ^[2]				Dosage:	0.3 or 1 mg/kg				Administration:	i.v. or s.c.				Result:	Pharmacokinetic profile of Nemvaleukin alfa.				Dose Route	dose (mg/kg)	C _{max} (ng/mL)	T _{max} (h)	T _{1/2} (h)	i.v.	0.3	6119	0.083	49.5
Animal Model:	SCLC orthotopic model ^[1]																																																						
Dosage:	6 mg/kg																																																						
Administration:	s.c., every 4 days																																																						
Result:	Delayed tumor growth and prolonged survival.																																																						
Animal Model:	Male cynomolgus monkeys (PK Assay) ^[2]																																																						
Dosage:	0.3 or 1 mg/kg																																																						
Administration:	i.v. or s.c.																																																						
Result:	Pharmacokinetic profile of Nemvaleukin alfa.																																																						
Dose Route	dose (mg/kg)	C _{max} (ng/mL)	T _{max} (h)	T _{1/2} (h)																																																			
i.v.	0.3	6119	0.083	49.5																																																			

s.c.	0.3	549	8	61.9
s.c.	1	1035	8	37.3

REFERENCES

- [1]. Pan Y, et al, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer. J Immunother Cancer. 2022 Sep;10(9):e004913.
- [2]. Lopes JE, et al. Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys. J Pharmacol Exp Ther. 2021 Nov;379(2):203-210.
- [3]. Lopes JE, et al. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA